JP2024529839A - Nlrp3モジュレーター - Google Patents

Nlrp3モジュレーター Download PDF

Info

Publication number
JP2024529839A
JP2024529839A JP2023580379A JP2023580379A JP2024529839A JP 2024529839 A JP2024529839 A JP 2024529839A JP 2023580379 A JP2023580379 A JP 2023580379A JP 2023580379 A JP2023580379 A JP 2023580379A JP 2024529839 A JP2024529839 A JP 2024529839A
Authority
JP
Japan
Prior art keywords
alkyl
pharma
solvate
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529839A5 (cg-RX-API-DMAC7.html
Inventor
コリンズ,ジェームズ
ボルー,ヴェンカット
ユアン,シャンドン
ナス,ジョン
Original Assignee
ズーマゲン バイオサイエンシーズ エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ズーマゲン バイオサイエンシーズ エルティーディー filed Critical ズーマゲン バイオサイエンシーズ エルティーディー
Publication of JP2024529839A publication Critical patent/JP2024529839A/ja
Publication of JP2024529839A5 publication Critical patent/JP2024529839A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023580379A 2021-06-29 2022-06-28 Nlrp3モジュレーター Pending JP2024529839A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163216446P 2021-06-29 2021-06-29
US63/216,446 2021-06-29
US202263320155P 2022-03-15 2022-03-15
US63/320,155 2022-03-15
PCT/US2022/035306 WO2023278438A1 (en) 2021-06-29 2022-06-28 Nlrp3 modulators

Publications (2)

Publication Number Publication Date
JP2024529839A true JP2024529839A (ja) 2024-08-14
JP2024529839A5 JP2024529839A5 (cg-RX-API-DMAC7.html) 2025-06-30

Family

ID=84692056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580379A Pending JP2024529839A (ja) 2021-06-29 2022-06-28 Nlrp3モジュレーター

Country Status (5)

Country Link
US (1) US20240327413A1 (cg-RX-API-DMAC7.html)
EP (1) EP4362946A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024529839A (cg-RX-API-DMAC7.html)
TW (1) TW202319054A (cg-RX-API-DMAC7.html)
WO (1) WO2023278438A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023003002A1 (cg-RX-API-DMAC7.html) * 2021-07-21 2023-01-26
JP2024534162A (ja) * 2021-08-25 2024-09-18 ピーティーシー セラピューティクス, インコーポレイテッド Nlrp3の阻害剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
PL4363406T3 (pl) 2021-07-02 2026-01-05 Astrazeneca Ab Inhibitory inflamasomu nlrp3
CN118302417A (zh) * 2021-08-25 2024-07-05 Ptc医疗公司 Nlrp3抑制剂
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
CN118234730A (zh) * 2021-11-17 2024-06-21 豪夫迈·罗氏有限公司 杂环nlrp3抑制剂
EP4499646A4 (en) * 2022-03-31 2026-03-18 Hangzhou Highlightll Pharmaceutical Co Ltd NLRP3 Inflammasome Inhibitors
WO2024006559A1 (en) * 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
JP2025524640A (ja) * 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
CN120569372A (zh) * 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
EP4658649A1 (en) * 2023-01-31 2025-12-10 Janssen Pharmaceutica NV [1,2,4]triazolo[4,3-a]pyridines and [1,2,4]triazolo[4,3-a]pyrazines as nlrp3 inhibitors
JP2026504422A (ja) 2023-01-31 2026-02-05 ヤンセン ファーマシューティカ エヌ.ベー. NLRP3阻害剤としてのピロロ[1,2-d][1,2,4]トリアジン及びピラゾロ[1,5-d][1,2,4]トリアジン
WO2024160692A1 (en) * 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
TW202448892A (zh) * 2023-04-17 2024-12-16 大陸商上海拓界生物醫藥科技有限公司 稠合噠嗪類衍生物及其用途
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
WO2026082103A1 (zh) * 2024-10-16 2026-04-23 青岛博森泰科技有限公司 一种nlrp3抑制剂用于预防和/或治疗与体重增加相关的疾病或病症的用途
WO2026082092A1 (zh) * 2024-10-16 2026-04-23 青岛博森泰科技有限公司 一种nlrp3抑制剂用于治疗炎症的用途
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507479A (ja) * 1999-08-23 2003-02-25 メルク シャープ エンド ドーム リミテッド Gaba受容体リガンドとしてのイミダゾ−トリアジン誘導体
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
WO2020234715A1 (en) * 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
WO2021009567A1 (en) * 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
WO2023159148A2 (en) * 2022-02-18 2023-08-24 Ptc Therapeutics, Inc. Inhibitors of nlrp3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EP1745039A4 (en) * 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507479A (ja) * 1999-08-23 2003-02-25 メルク シャープ エンド ドーム リミテッド Gaba受容体リガンドとしてのイミダゾ−トリアジン誘導体
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
WO2020234715A1 (en) * 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
WO2021009567A1 (en) * 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
WO2023159148A2 (en) * 2022-02-18 2023-08-24 Ptc Therapeutics, Inc. Inhibitors of nlrp3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERLINDE FRENZEN, MONIKA RISCHKE UND GUNTHER SEITZ: "Thermisch induzierte formale [3 + 2]-Cycloadditionen von 3,3-Dimethoxycyclopropen an Triazine, eine", CHEMISCHE BERICHTE, vol. 126(10), JPN7026001549, October 1993 (1993-10-01), DE, pages 2317 - 2323, ISSN: 0005833067 *
ROLF PAUL, JOHN A. BROCKMAN, W. A. HALLETT, JOHN W. HANIFIN, M. ERNESTINE TARRANT, LAWRENCE W. TORLE: "Imidazo[1,5-d][1,2,4]triazines as Potential Antiasthma Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 28(11), JPN7026001550, 1 November 1985 (1985-11-01), US, pages 1704 - 1716, ISSN: 0005833068 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023003002A1 (cg-RX-API-DMAC7.html) * 2021-07-21 2023-01-26
JP2024534162A (ja) * 2021-08-25 2024-09-18 ピーティーシー セラピューティクス, インコーポレイテッド Nlrp3の阻害剤

Also Published As

Publication number Publication date
EP4362946A4 (en) 2025-05-21
EP4362946A1 (en) 2024-05-08
US20240327413A1 (en) 2024-10-03
TW202319054A (zh) 2023-05-16
WO2023278438A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
WO2023278438A1 (en) Nlrp3 modulators
JP7595642B2 (ja) Nlrp3モジュレーター
CN114555571B (zh) 作为NLRP3调节剂的N-((1,2,3,5,6,7-六氢-s-引达省-4-基)氨甲酰基)-4,5,6,7-四氢苯并呋喃-2-磺酰胺衍生物
JP7595582B2 (ja) Tyk2偽キナーゼリガンド
US11603375B2 (en) NLRP3 modulators
JP2025509697A (ja) Nlrp3モジュレーター
US9790191B2 (en) Substituted acylaminopyrimidines as inducers of alpha interferon production
CN117881401A (zh) Nlrp3调节剂
WO2025059069A1 (en) Nlrp3 modulators
WO2023137353A1 (en) 15-pgdh inhibitors
EA049038B1 (ru) Модуляторы nlrp3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260406

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260703